Generalized peeling skin syndrome (PSS) is an autosomal recessive genodermatosis characterized by lifelong, continuous shedding of the upper epidermis. Using whole-genome homozygozity mapping and whole-exome sequencing, we identified a novel homozygous missense mutation (c.229C>T, R77W) within the CHST8 gene, in a large consanguineous family with non-inflammatory PSS type A. CHST8 encodes a Golgi transmembrane N-acetylgalactosamine-4-O-sulfotransferase (GalNAc4-ST1), which we show by immunofluorescence staining to be expressed throughout normal epidermis. A colorimetric assay for total sulfated glycosaminoglycan (GAG) quantification, comparing human keratinocytes (CCD1106 KERTr) expressing wild type and mutant recombinant GalNAc4-ST1, revealed decreased levels of total sulfated GAGs in cells expressing mutant GalNAc4-ST1, suggesting loss of function. Western blotting revealed lower expression levels of mutant recombinant GalNAc4-ST1 compared to wild type, suggesting that accelerated degradation may result in loss of function, leading to PSS type A. This is the first report describing a mutation as the cause of PSS type A.
Generalized peeling skin syndrome (n class="Gene">PSS) is an autosomal recessive genodermatosis characterized by lifelong, continuous shedding of the upper epidermis. Using whole-genome homozygozity mapping and whole-exome sequencing, we identified a novel homozygous missense mutation (c.229C>T, R77W) within the CHST8 gene, in a large consanguineous family with non-inflammatory PSS type A. CHST8 encodes a Golgi transmembrane N-acetylgalactosamine-4-O-sulfotransferase (GalNAc4-ST1), which we show by immunofluorescence staining to be expressed throughout normal epidermis. A colorimetric assay for total sulfated glycosaminoglycan (GAG) quantification, comparing human keratinocytes (CCD1106 KERTr) expressing wild type and mutant recombinant GalNAc4-ST1, revealed decreased levels of total sulfated GAGs in cells expressing mutant GalNAc4-ST1, suggesting loss of function. Western blotting revealed lower expression levels of mutant recombinant GalNAc4-ST1 compared to wild type, suggesting that accelerated degradation may result in loss of function, leading to PSS type A. This is the first report describing a mutation as the cause of PSS type A.
Authors: N O Dávalos; A García-Vargas; J Pforr; I P Dávalos; V J Picos-Cárdenas; D García-Cruz; R Kruse; L E Figuera; M M Nöthen; R C Betz Journal: Br J Dermatol Date: 2005-12 Impact factor: 9.302
Authors: Andrew J Cassidy; Maurice A M van Steensel; Peter M Steijlen; Michel van Geel; Jaap van der Velden; Susan M Morley; Alessandro Terrinoni; Gerry Melino; Eleonora Candi; W H Irwin McLean Journal: Am J Hum Genet Date: 2005-10-11 Impact factor: 11.025
Authors: Zhimiao Lin; Jiahui Zhao; Daniela Nitoiu; Claire A Scott; Vincent Plagnol; Frances J D Smith; Neil J Wilson; Christian Cole; Mary E Schwartz; W H Irwin McLean; Huijun Wang; Cheng Feng; Lina Duo; Eray Yihui Zhou; Yali Ren; Lanlan Dai; Yulan Chen; Jianguo Zhang; Xun Xu; Edel A O'Toole; David P Kelsell; Yong Yang Journal: Am J Hum Genet Date: 2015-02-12 Impact factor: 11.025
Authors: Marta Vicioso-Mantis; Raquel Fueyo; Claudia Navarro; Sara Cruz-Molina; Wilfred F J van Ijcken; Elena Rebollo; Álvaro Rada-Iglesias; Marian A Martínez-Balbás Journal: Nat Commun Date: 2022-06-07 Impact factor: 17.694
Authors: Alessandro Salvi; Edoardo Giacopuzzi; Elena Bardellini; Francesca Amadori; Lia Ferrari; Giuseppina De Petro; Giuseppe Borsani; Alessandra Majorana Journal: Int J Mol Med Date: 2016-09-19 Impact factor: 4.101